Phase II study of Carboplatin + nab-Paclitaxel followed by nab-Paclitaxel with chemotherapy naive advanced Non- Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 31 May 2016 Planned number of patients changed from 20 to 40.
- 15 Sep 2014 New trial record